Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) Equity Average (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Equity Average for 8 consecutive years, with $54.4 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 10.21% to $54.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.4 million through Dec 2025, down 10.21% year-over-year, with the annual reading at $74.3 million for FY2025, 97.52% up from the prior year.
  • Equity Average for Q4 2025 was $54.4 million at Precision Biosciences, up from $25.3 million in the prior quarter.
  • The five-year high for Equity Average was $101.0 million in Q3 2021, with the low at $24.0 million in Q4 2023.
  • Average Equity Average over 5 years is $59.7 million, with a median of $55.2 million recorded in 2024.
  • The sharpest move saw Equity Average tumbled 66.91% in 2023, then skyrocketed 153.02% in 2024.
  • Over 5 years, Equity Average stood at $96.3 million in 2021, then fell by 24.82% to $72.4 million in 2022, then crashed by 66.91% to $24.0 million in 2023, then surged by 153.02% to $60.6 million in 2024, then decreased by 10.21% to $54.4 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $54.4 million, $25.3 million, and $41.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.